Tag: MSD
Merck & Co Announces Phase 3 Trial Initiations for MK-2870/SKB264
Merck & Co/MSD has initiated a pivotal Phase 3 trials for of its investigational antibody-drug conjugates (ADC) candidate MK-2870/SKB264, an innovative TROP2-targeting ADC being...
Kelun-Biotech Signs Oncology Research Collaboration Agreement with Merck/MSD
Chinese clinical-stage biotech company Kelun-Biotech*, a subsidiary of Sichuan Kelun Pharmaceutical, has signed an exclusive license agreement with Merck & Co/MSD to develop an...
SGN-LIV1A + Pembrolizumab to be Investigated as First Line Treatment for...
SGN-LIV1A an ADC in combination with Pembrolizumab for the treatment of mTNBC
Phase II PRECEDENT Trial of Vintafolide in Platinum-Resistant Ovarian Cancer Basis...
Based on trial results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145; Merck and Endocyte), an investigational folate small molecule drug conjugate or SMDC, published in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology, a regulatory application is currently under review with the European Medicines Agency for the treatment of folate-receptor positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin (PLD).
